Human Growth Hormone Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Human Growth Hormone Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global human growth hormone market size reached US$ 5.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.

HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults.

The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth. Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global human growth hormone market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application, distribution channel and route of administration.

Breakup by Application:

Growth Hormone (GH) Deficiency

Adult GH Deficiency
Pediatric GH Deficiency


Turner Syndrome
Idiopathic Short Stature (ISS)
Prader-Willi Syndrome (PWS)
Small for Gestational Age
Others


Breakup by Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others


Breakup by Route of Administration:

Intravenous
Intramuscular
Subcutaneous
Oral


Breakup by Region:

North America

United States
Canada


Asia Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others


Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others


Latin America

Brazil
Mexico
Others


Middle East and Africa


Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc.

Key Questions Answered in This Report:

How has the global human growth hormone market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global human growth hormone market?
What are the key regional markets?
What is the breakup of the market based on the application?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the route of administration?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global human growth hormone market and who are the key players?
What is the degree of competition in the industry?